Shots:

• The US FDA has approved Pipeline Flex Embolization Device with a Shield Technology to advance flow diversion therapy that demonstrates a reduction in material thrombogenicity or a reduction in the tendency of the surface treatment material to create clots
• The first patient receives new shield surface modification at NYU Langone Health. The SHIELD study evaluates the safety and efficacy of third-generation pipeline embolization device with shield technology for intracranial aneurysms
• The SHIELD study results showed 77.2% complete aneurysm occlusion @12 mos.- 3.2% primary safety endpoint- and 93.1% complete wall apposition post-procedure

  Ref: Medtronic | Image: Seeking Alpha